Login
Home
Charts
Search
Watchlist
Products

Glenmark Pharmaceuticals Ltd

GLENMARK·NSE
₹2,430.40-1.80%Thu, 24 Sept '26 15:52
Industry:Pharma - Formulators
Indices:

Glenmark Pharmaceuticals Ltd

GLENMARK
NSE
₹2,430.40
-1.80%
|Thu, 24 Sept '26 15:52
SOICxStockScans Reports
Industry
Pharma - Formulators
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹68,592Cr
Close
Close Price
₹2,430.40
Industry
Industry
Pharma - Formulators
PE
Price To Earnings
38.15
PS
Price To Sales
3.87
Revenue
Revenue
₹17,737Cr
Rev Gr TTM
Revenue Growth TTM
32.94%
PAT Gr TTM
PAT Growth TTM
138.48%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
3,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,018
Growth YoY
Revenue Growth YoY%
6.3-19.12.16.87.135.16.30.676.115.215.823.1
Expenses
ExpensesCr
2,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,214
Operating Profit
Operating ProfitCr
462-2095045886026005615812,360870763805
OPM
OPM%
14.4-8.316.518.117.517.717.217.839.022.320.220.0
Other Income
Other IncomeCr
-324-31326313931-361-297-1,184-140-18466
Interest Expense
Interest ExpenseCr
121134149404852675866414354
Depreciation
DepreciationCr
141147151118120123125130141154148173
PBT
PBTCr
-124-521531462473456896967534388643
Tax
TaxCr
56-721,76912211810844935713186161
PAT
PATCr
-62-331-1,214340354348447610403301483
Growth YoY
PAT Growth YoY%
-122.1-213.8-201.296.5675.8205.2100.4-86.272.215.96,779.4928.0
NPM
NPM%
-1.9-13.2-39.610.510.310.30.11.410.110.38.012.0
EPS
EPS₹
-2.9-12.4-43.212.112.612.30.21.721.614.310.717.1
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
3,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,018
Growth YoY
Revenue Growth YoY%
6.3-19.12.16.87.135.16.30.676.115.215.823.1
Expenses
ExpensesCr
2,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,214
Operating Profit
Operating ProfitCr
462-2095045886026005615812,360870763805
OPM
OPM%
14.4-8.316.518.117.517.717.217.839.022.320.220.0
Other Income
Other IncomeCr
-324-31326313931-361-297-1,184-140-18466
Interest Expense
Interest ExpenseCr
121134149404852675866414354
Depreciation
DepreciationCr
141147151118120123125130141154148173
PBT
PBTCr
-124-521531462473456896967534388643
Tax
TaxCr
56-721,76912211810844935713186161
PAT
PATCr
-62-331-1,214340354348447610403301483
Growth YoY
PAT Growth YoY%
-122.1-213.8-201.296.5675.8205.2100.4-86.272.215.96,779.4928.0
NPM
NPM%
-1.9-13.2-39.610.510.310.30.11.410.110.38.012.0
EPS
EPS₹
-2.9-12.4-43.212.112.612.30.21.721.614.310.717.1

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,98317,737
Growth
Revenue Growth%
14.120.1-0.18.77.92.912.4-5.92.012.827.532.9
Expenses
ExpensesCr
6,1257,0437,4598,2808,9438,8609,9859,94810,61810,97012,41012,940
Operating Profit
Operating ProfitCr
1,4372,0371,6151,5861,6982,0842,3201,6351,1952,3514,5724,797
OPM
OPM%
19.022.417.816.116.019.118.914.110.117.626.927.0
Other Income
Other IncomeCr
20-449137519295-94-477-61-259-1,805-1,443
Interest Expense
Interest ExpenseCr
179237286335377353298349516207209204
Depreciation
DepreciationCr
234264302326417444487569582486573617
PBT
PBTCr
1,0441,4911,1191,3011,0961,3821,441240371,3991,9852,533
Tax
TaxCr
3013833153763204124483291,867352623735
PAT
PATCr
7431,109804925776970994-90-1,8311,0471,3621,798
Growth
PAT Growth%
56.449.2-27.515.1-16.125.02.4-109.0-1,944.3157.230.1138.5
NPM
NPM%
9.812.28.99.47.38.98.1-0.8-15.57.98.010.1
EPS
EPS₹
25.639.328.532.827.534.433.410.5-53.237.148.363.7
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
7,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,98317,737
Growth
Revenue Growth%
14.120.1-0.18.77.92.912.4-5.92.012.827.532.9
Expenses
ExpensesCr
6,1257,0437,4598,2808,9438,8609,9859,94810,61810,97012,41012,940
Operating Profit
Operating ProfitCr
1,4372,0371,6151,5861,6982,0842,3201,6351,1952,3514,5724,797
OPM
OPM%
19.022.417.816.116.019.118.914.110.117.626.927.0
Other Income
Other IncomeCr
20-449137519295-94-477-61-259-1,805-1,443
Interest Expense
Interest ExpenseCr
179237286335377353298349516207209204
Depreciation
DepreciationCr
234264302326417444487569582486573617
PBT
PBTCr
1,0441,4911,1191,3011,0961,3821,441240371,3991,9852,533
Tax
TaxCr
3013833153763204124483291,867352623735
PAT
PATCr
7431,109804925776970994-90-1,8311,0471,3621,798
Growth
PAT Growth%
56.449.2-27.515.1-16.125.02.4-109.0-1,944.3157.230.1138.5
NPM
NPM%
9.812.28.99.47.38.98.1-0.8-15.57.98.010.1
EPS
EPS₹
25.639.328.532.827.534.433.410.5-53.237.148.363.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
2828282828282828282828
Reserves
ReservesCr
3,6014,4645,1355,5776,0427,0369,0589,4467,8208,82110,484
Current Liabilities
Current LiabilitiesCr
3,9992,7033,2884,0214,1264,2014,6895,1055,8195,9676,376
Non Current Liabilities
Non Current LiabilitiesCr
2,5644,5694,1443,6634,4894,3382,9564,4276921,2333,020
Total Liabilities
Total LiabilitiesCr
10,19311,76412,59513,28914,68515,60417,08319,37214,35916,05019,908
Current Assets
Current AssetsCr
5,9046,8756,9896,6976,8047,3608,28210,7267,4289,29511,300
Non Current Assets
Non Current AssetsCr
4,2894,8895,6076,5927,8818,2448,8018,6466,9316,7548,608
Total Assets
Total AssetsCr
10,19311,76412,59513,28914,68515,60417,08319,37214,35916,05019,908
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
2828282828282828282828
Reserves
ReservesCr
3,6014,4645,1355,5776,0427,0369,0589,4467,8208,82110,484
Current Liabilities
Current LiabilitiesCr
3,9992,7033,2884,0214,1264,2014,6895,1055,8195,9676,376
Non Current Liabilities
Non Current LiabilitiesCr
2,5644,5694,1443,6634,4894,3382,9564,4276921,2333,020
Total Liabilities
Total LiabilitiesCr
10,19311,76412,59513,28914,68515,60417,08319,37214,35916,05019,908
Current Assets
Current AssetsCr
5,9046,8756,9896,6976,8047,3608,28210,7267,4289,29511,300
Non Current Assets
Non Current AssetsCr
4,2894,8895,6076,5927,8818,2448,8018,6466,9316,7548,608
Total Assets
Total AssetsCr
10,19311,76412,59513,28914,68515,60417,08319,37214,35916,05019,908

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3456571,6481,3241,3921,1311,109625-265-8283,445
Investing Cash Flow
Investing Cash FlowCr
-880-712-1,013-699-784-675-333-5284,5612-1,283
Financing Cash Flow
Financing Cash FlowCr
699543-469-739-445-442-520-77-3,906787-2,709
Net Cash Flow
Net Cash FlowCr
93199177-2971741425519389-38-547
Free Cash Flow
Free Cash FlowCr
-544-766259061645632075-1,162-1,5762,090
CFO To PAT
CFO To PAT%
46.459.3205.0143.2179.4116.6111.6-698.314.5-79.0252.9
CFO To EBITDA
CFO To EBITDA%
24.032.3102.083.582.054.347.838.3-22.2-35.275.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3456571,6481,3241,3921,1311,109625-265-8283,445
Investing Cash Flow
Investing Cash FlowCr
-880-712-1,013-699-784-675-333-5284,5612-1,283
Financing Cash Flow
Financing Cash FlowCr
699543-469-739-445-442-520-77-3,906787-2,709
Net Cash Flow
Net Cash FlowCr
93199177-2971741425519389-38-547
Free Cash Flow
Free Cash FlowCr
-544-766259061645632075-1,162-1,5762,090
CFO To PAT
CFO To PAT%
46.459.3205.0143.2179.4116.6111.6-698.314.5-79.0252.9
CFO To EBITDA
CFO To EBITDA%
24.032.3102.083.582.054.347.838.3-22.2-35.275.3

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
22,41224,20314,87418,2155,81413,10812,47713,12127,02043,45860,20268,592
Price To Earnings
Price To Earnings
30.221.818.519.77.513.513.344.241.544.238.1
Price To Sales
Price To Sales
3.02.71.61.90.61.21.01.12.33.33.53.9
Price To Book
Price To Book
6.25.42.93.31.01.91.41.43.44.95.76.5
EV To EBITDA
EV To EBITDA
17.313.711.213.35.48.16.510.122.318.813.014.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
62.064.558.757.758.059.657.057.355.261.167.167.1
OPM
OPM%
19.022.417.816.116.019.118.914.110.117.626.927.0
NPM
NPM%
9.812.28.99.47.38.98.1-0.8-15.57.98.010.1
ROCE
ROCE%
17.718.814.617.314.014.413.34.26.114.219.819.8
ROE
ROE%
20.524.715.616.512.813.710.9-0.9-23.311.813.013.0
ROA
ROA%
7.39.46.47.05.36.25.8-0.5-12.86.56.86.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
22,41224,20314,87418,2155,81413,10812,47713,12127,02043,45860,20268,592
Price To Earnings
Price To Earnings
30.221.818.519.77.513.513.344.241.544.238.1
Price To Sales
Price To Sales
3.02.71.61.90.61.21.01.12.33.33.53.9
Price To Book
Price To Book
6.25.42.93.31.01.91.41.43.44.95.76.5
EV To EBITDA
EV To EBITDA
17.313.711.213.35.48.16.510.122.318.813.014.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
62.064.558.757.758.059.657.057.355.261.167.167.1
OPM
OPM%
19.022.417.816.116.019.118.914.110.117.626.927.0
NPM
NPM%
9.812.28.99.47.38.98.1-0.8-15.57.98.010.1
ROCE
ROCE%
17.718.814.617.314.014.413.34.26.114.219.819.8
ROE
ROE%
20.524.715.616.512.813.710.9-0.9-23.311.813.013.0
ROA
ROA%
7.39.46.47.05.36.25.8-0.5-12.86.56.86.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Glenmark Pharmaceuticals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/as-12ecaf5fd59a5140bbad1dfa.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/isbnxy4mjg6oalfofvez0636.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/1t212b6mbat6orwu15mnfmsf.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/ewvley06nmw0szoiw9jvwf4y.pdf
  • Q1 FY2026 Earnings Call Transcript (Jun 2025, PDF): https://www.stockscans.in/document/znfd7ceuegnxphgd2f9q9vwe.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/jmr61c1s18xxqd58py8irf6i.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/vznnl007us985kawsms622sq.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/ceiycdppcld8olgb3wxfzs8i.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/9gmm5glijpx052z6p4nctwhw.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/ofqvb7e99z724xfe23f07462.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/5w16gpx8t2arqtgbb1ayb3xc.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/u311cgrgiaq1mce6o2pg5ei7.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/f06dqvcffctbpwq5n8urz7zr.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/7675eexwwr0ljchhnfvqxr3l.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/9noxk33vluojy8oqjqicv3l2.pdf
  • Q4 FY2024 Quarterly Result (Mar 2024, PDF): https://www.stockscans.in/document/kjtz3bkdzvv7mb9kzn291qzv.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/egs8oy4e8t6miwtdstnhdpmv.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/r4snljqzxxo69yroc86t5388.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/raiwqc23196bwe7nvkiane3g.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/bllryx1nn3xewc5vo4yonqcq.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/dzqza2vauy03jsexbj3dfo3o.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/3xd32puot077o2jgwgd5pjp6.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/um2zf6umtwhetxnra2232siq.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/t2s91z9x1aeg27baujr4zsfn.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/cta72ued6bnpwpkp9nn6hzch.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/pxx6fdfg64fpiutxd4c3qpwc.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/qkf7q9oam5p4r2or33o8kf0y.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/7dzoftxx959v7smwoxh2rdd5.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/1uzdwtpifem0196klr2v45po.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/b67f7hima46xe07dtopnsehs.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/6mtdrjx5i448egm11k6bec4v.pdf

Concall Transcript Summaries — Glenmark Pharmaceuticals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202606/as-12ecaf5fd59a5140bbad1dfa.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202603/isbnxy4mjg6oalfofvez0636.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202512/1t212b6mbat6orwu15mnfmsf.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202509/ewvley06nmw0szoiw9jvwf4y.pdf
  • Q1 FY2026 Concall Transcript Summary (Jun 2025): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202506/znfd7ceuegnxphgd2f9q9vwe.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202503/jmr61c1s18xxqd58py8irf6i.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202412/vznnl007us985kawsms622sq.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AGLENMARK/transcript-notes/202409/ceiycdppcld8olgb3wxfzs8i.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies